Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 688 across all filing types
Latest filing 2020-02-19 Report Publication Anno…
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva to present at the Cowen and Company 40th Annual Health Care Conference
Report Publication Announcement Classification · 99% confidence The document is explicitly titled a "PRESS RELEASE" announcing that the company "Inventiva to present at the Cowen and Company 40th Annual Health Care Conference." It details the date, time, and location of the presentation and mentions that the presentation document and webcast link will be available in the 'Investors' – 'Investor Presentations' section of the company website. This content is a direct announcement about an upcoming investor event/presentation, which aligns perfectly with the definition of an Investor Presentation (IP). Although it is a press release, the core subject matter is the presentation itself, not a general regulatory filing (RNS) or a report publication announcement (RPA) about a financial report.
2020-02-19 English
Inventiva participera à la « Cowen and Company 40th Annual Health Care Conference »
Investor Presentation Classification · 98% confidence The document is a press release announcing that the CEO of Inventiva will be presenting at the 'Cowen and Company 40th Annual Health Care Conference'. It details the date, time, and location of the presentation and mentions that the presentation document and webcast link will be available in the 'Investor Presentations' section of the company website. This content directly relates to materials prepared for investors regarding the company's strategy and pipeline, which aligns perfectly with the definition of an Investor Presentation (IP). Although it is an announcement about a presentation, the core subject matter is the presentation itself, making IP a stronger fit than RPA or ER, as it is not a financial results release.
2020-02-19 French
Déclaration d'intention
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Déclaration d'intention (articles L. 233-7 du code de commerce)" and details a declaration made by BVF Partners, LP regarding its shareholding in INVENTIVA. This type of filing, which reports on significant changes in share ownership or intentions related to holdings, directly corresponds to the definition of a Major Shareholding Notification. The French legal reference (L. 233-7 du code de commerce) confirms this is a mandatory disclosure related to ownership thresholds. Therefore, the appropriate code is MRQ.
2020-02-17 French
Franchissement de seuils
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de franchissement de seuils (articles L. 233-7 du code de commerce)" which translates to a declaration of crossing ownership thresholds under French commercial code. It details that BVF Partners, LP crossed ownership thresholds (15% of voting rights and 25% of capital) in INVENTIVA. This type of filing specifically reports changes in significant share ownership levels by an entity, which directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal regulatory disclosure regarding shareholding changes, not a general regulatory announcement (RNS) or a report itself.
2020-02-17 French
Franchissement de seuil et déclaration d'intention
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuil et déclaration d'intention" (Declaration of crossing a threshold and declaration of intent) and explicitly references articles L. 233-7 of the French Commercial Code. It details that New Enterprise Associates 17 L.P. crossed the 10% voting rights threshold of INVENTIVA on February 11, 2020, due to subscribing to a capital increase. This type of filing, which reports changes in significant share ownership (crossing thresholds), directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal regulatory disclosure regarding ownership changes, not a general earnings release, annual report, or proxy statement.
2020-02-13 French
Franchissements de seuils
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Déclaration de franchissements de seuils (article L. 233-7 du code de commerce)" and details changes in share ownership and voting rights percentages for a concert group (M. Pierre Broqua and the Frédéric Cren family group) in the company INVENTIVA. This type of filing specifically reports when an individual or group crosses predefined thresholds of share ownership or voting rights, which directly corresponds to the definition of a Major Shareholding Notification (MRQ). Although it involves share transactions, the focus is on the resulting threshold crossing notification, not the company's own share repurchase (POS) or insider trading by a single director (DIRS).
2020-02-13 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.